The Journal of Clinical and Aesthetic Dermatology
JCAD's audio platform provides interviews with leading experts in the dermatology field. The podcast covers clinical and aesthetic dermatology topics, offering insights from specialists. It is produced by Matrix Medical Communications.
Episodes
Saakshi Khattri, MD: Evaluating the Newest Data in CLE
Send us Fan MailDr. Khattri looks at the 52-week findings from the ongoing phase 2/3 AMETHYST trial evaluating litifilimab in cutaneous lupus erythematosus (CLE), which were presented at the EADV Congress 2026. She notes that there are currently no FDA-approved targeted therapies for CLE, a disease that can cause permanent scarring, dyspigmentation, and scarring alopecia. Litifilimab, a monoclonal
Nicholas Brownstone, MD: Achieving Long-Term Success in Psoriasis
Send us Fan MailDr. Brownstone discusses the place of risankizumab in the psoriasis and psoriatic arthritis treatment landscape. He discusses risankizumab’s durable response, infrequent dosing, and favorable long-term and short-term safety profiles. Dr. Brownstone references the UltIMMa-1 (NCT02684370) and UltIMMa-2 (NCT02684357) trials, which demonstrated the superior efficacy of risankizumab vs
James Del Rosso, DO: JCAD September 2026 Issue Highlights
Send us Fan MailDr. Del Rosso, DO, the Editor-in-Chief of the Journal of Clinical and Aesthetic Dermatology, discusses highlights from new research published in the September 2026 issue of JCAD.
Claudia Günther, MD, PhD: Analysis of Phase 2 CLE Trial With Litifilimab
Send us Fan MailDr. Günther discusses her poster from the European Academy of Dermatology and Venereology Congress 2026 on transcriptomic analyses of the phase 2 LILAC trial Part B. The study examined how litifilimab affects the underlying biology of cutaneous lupus erythematosus (CLE). RNA sequencing demonstrated broad immune dysregulation in patients with CLE and showed that treatment with litif
Joseph Fakhoury, MD: Special Considerations in Severe Alopecia Areata
Send us Fan MailDr. Fakhoury discusses the use of systemic treatment for patients with severe alopecia areata. He highlights data from the THRIVE-AA1 and THRIVE-AA2 clinical trials, which showed effective results with deuruxilitinib vs placebo in this patient population. Additionally, he emphasizes that the indications for severe alopecia areata have expanded to those with a Severity of Alopecia T
Raj Chovatiya, MD, PhD, MSCI: Intravenous vs Subcutaneous GPP Therapy
Send us Fan MailDr. Chovatiya reviews generalized pustular psoriasis (GPP) as a distinct, potentially life-threatening inflammatory dermatosis characterized by acute flares and periods of relative quiescence. He highlights the diagnostic challenges in differentiating GPP from plaque psoriasis and other pustular disorders, as well as the central role of interleukin (IL)-36 pathway dysregulation in
James Del Rosso, DO: JCAD August 2026 Issue Highlights
Send us Fan MailDr. Del Rosso, DO, the Editor-in-Chief of the Journal of Clinical and Aesthetic Dermatology, discusses highlights from new research published in the August 2026 issue of JCAD.
Jeffrey Cohen, MD, MPH: Treating Psoriasis in High-Impact Sites
Send us Fan MailDr. Cohen discusses the treatment of psoriasis in high-impact sites. He outlines how to approach these special considerations and provides treatment options, including the utilization of biologics like risankizumab. He also reviews considerations for unique cases such as nail psoriasis and palmoplantar psoriasis.
Jason Hawkes, MD, MS: The IL-36 Inflammatory Pathway and Generalized Pustular Psoriasis
Send us Fan MailAhead of National Generalized Pustular Psoriasis (GPP) Awareness Day, Dr. Hawkes gives an overview of the distinct clinical and immunologic features of GPP, emphasizing how this rare, life-threatening disease differs from plaque psoriasis in both presentation and underlying pathophysiology. He highlights the central role of interleukin-36 (IL-36) dysregulation in GPP, explains why
James Del Rosso, DO: JCAD July 2026 Issue Highlights
Send us Fan MailJames Del Rosso, DO, the Editor-in-Chief of the Journal of Clinical and Aesthetic Dermatology, discusses highlights from new research published in the July 2026 issue of JCAD.
Fabrizio Galimberti, MD, PhD: The Importance of Targeted Therapy for GPP Treatment
Send us Fan MailFabrizio Galimberti, MD, PhD, reviews the molecular biology behind spesolimab for the treatment of generalized pustular psoriasis (GPP). He highlights the distinction between psoriasis and GPP, while discussing the role that the interleukin-36 pathway plays in inflammation. Dr. Galimberti emphasizes the importance of targeted treatment for flare reduction and improved outcomes in G
James Del Rosso, DO: JCAD June 2026 Issue Highlights
Send us Fan MailJames Del Rosso, DO, the Editor-in-Chief of the Journal of Clinical and Aesthetic Dermatology, discusses highlights from new research published in the June 2026 issue of JCAD.
Tina Bhutani, MD, MAS, FAAD: Use of Spesolimab for Generalized Pustular Psoriasis
Send us Fan MailTina Bhutani, MD, MAS, FAAD, discusses the use of spesolimab, an interleukin-36 receptor blocker, for the treatment of patients with generalized pustular psoriasis. Drawing on real-world patient cases, she highlights its role in rapidly controlling acute flares, improving patient quality of life, and reducing reliance on therapies originally developed for plaque psoriasis.
James Del Rosso, DO: JCAD May 2026 Issue Highlights
Send us Fan MailJames Del Rosso, DO, the Editor-in-Chief of the Journal of Clinical and Aesthetic Dermatology, discusses highlights from new research published in the May 2026 issue of JCAD.
Bruce Strober, MD, PhD, FAAD: Providing Care With Risankizumab in Psoriasis
Send us Fan MailBruce Strober, MD, PhD, FAAD, a clinical professor of dermatology at Yale University, discusses his extensive experience in treating patients with psoriasis. He describes his experience treating these patients with risankizumab (Skyrizi), highlighting its efficacy in treating chronic plaque psoriasis and its effectiveness for patients with comorbidities. The therapy has shown rapid
James Del Rosso, DO: JCAD April 2026 Issue Highlights
Send us Fan MailJames Del Rosso, DO, the Editor-in-Chief of the Journal of Clinical and Aesthetic Dermatology, discusses highlights from new research published in the April 2026 issue of JCAD.
James Del Rosso, DO, and Joseph Merola, MD, MMSc: What’s New in Cutaneous Lupus Erythematosus
Send us Fan MailJames Del Rosso, DO, and Joseph Merola, MD, MMSc, discuss recent advances in the treatment of cutaneous lupus erythematosus (CLE). They emphasize the importance of early detection and appropriate laboratory testing to differentiate between cutaneous-only disease and systemic lupus. They highlight the late-breaking phase 2/3 AMETHYST trial (NCT05531565) data for litifilimab, which s
James Del Rosso, DO, Diego Dasilva, MD, and Graham Litchman, DO, MS: Management of Severe Nail Psoriasis and Early Psoriatic Arthritis
Send us Fan MailJames Del Rosso, DO, Diego Ruiz Dasilva, MD, and Graham Litchman, DO, MS, discuss the clinical efficacy of bimekizumab (Bimzelx) for patients with severe fingernail psoriasis and concomitant psoriatic arthritis (PsA).They highlighted a case of a 56-year-old woman with extensive dystrophic changes across all 10 fingernails and PsA who had been misdiagnosed and treated for years with
James Del Rosso, DO, and David Cotter, MD, PhD: Clinical Management of Conjunctivitis, Erythema, and Arthralgia in AD
Send us Fan MailJames Del Rosso, DO, and David Cotter, MD, PhD, discuss the clinical safety and efficacy of nemolizumab for patients with atopic dermatitis (AD). They highlighted a case of an 11-year-old female patient with severe AD who switched from dupilumab (Dupixent) to nemolizumab (Nemluvio). The patient achieved rapid itch reduction and resolution of conjunctivitis and facial erythema. In a
James Del Rosso, DO: JCAD March 2026 Issue Highlights
Send us Fan MailJames Del Rosso, DO, the Editor-in-Chief of the Journal of Clinical and Aesthetic Dermatology, discusses highlights from new research published in the March 2026 issue of JCAD.
Ted Lain, MD, MBA: Long-Term Results of Deuruxolitinib for Alopecia Areata
Send us Fan MailTed Lain, MD, a board-certified dermatologist at Sanova Dermatology in Austin, Texas, shares his extensive experience with deuruxolitinib (Leqselvi) for the treatment of patients with moderate-to-severe alopecia areata. Drawing on 5 years of long-term extension data, Dr. Lain explains that patients generally maintained hair regrowth they achieved early in treatment, with no loss of
James Del Rosso, DO: JCAD February 2026 Issue Highlights
Send us Fan MailJames Del Rosso, DO, the Clinical Editor-in-Chief of the Journal of Clinical and Aesthetic Dermatology, discusses highlights from new research published in the February 2026 issue of JCAD.
James Del Rosso, DO, and David Cotter, MD, PhD: The Use of Gene-Expression Profile Testing for Effective Atopic Dermatitis Treatment
Send us Fan MailJames Del Rosso, DO, and David Cotter, MD, PhD, discuss using gene expression profile testing, such as the AdvanceAD-Tx test, to provide effective treatment for patients with atopic dermatitis. AdvanceAD-Tx allows clinicians to match therapy based on patients’ immune profiles using molecular testing. Drs. Del Rosso and Cotter also review the benefits of using the test not only at b
Amy McMichael, MD: Eight-Week Outcomes With Deuruxolitinib in Alopecia Areata
Send us Fan MailAmy McMichael, MD, a clinical professor and chair of the Department of Dermatology at Wake Forest School of Medicine, discusses deuruxolitinib for patients with alopecia areata. She highlights its 8-week efficacy compared to placebo in clinical trials. The medication provided significant improvement in hair regrowth at the 8-mg dose, with minimal adverse events. She emphasized the
Graham Litchman, DO, MS: Understanding Long-Term Treatment Success in a Patient With Psoriasis
Send us Fan MailGraham Litchman, DO, MS, a board-certified dermatologist at Vivida Dermatology in Las Vegas, Nevada, discusses a patient case involving a 54-year-old female patient with psoriasis who did not respond well to conventional treatments or systemic steroids. Dr. Lichtman introduced her to risankizumab (Skyrizi), explaining its mechanism of action, adverse events, and dosing schedule. Th
James Del Rosso, DO: JCAD January 2026 Issue Highlights
Send us Fan MailJames Del Rosso, DO, the Clinical Editor-in-Chief of the Journal of Clinical and Aesthetic Dermatology, discusses highlights from new research published in the January 2026 issue of JCAD.
Aaron Farberg, MD: Real-World Experiences in Alopecia Areata Treatment
Send us Fan MailDr. Aaron Farberg, a board-certified dermatologist and founder of Bear Dermatology in Dallas, Texas, discusses the evolving treatment landscape for alopecia areata with a focus on Janus kinase inhibitors and how he has used this type of treatment in his practice.
Arash Mostaghimi, MD, MPH, FAAD: Considerations for the Use of Deuruxolitinib in Patients with Alopecia Areata
Send us Fan MailDr. Mostaghimi discusses the speed and depth of efficacy of deuruxolitinib for providing hair regrowth in patients with severe alopecia areata.
James Del Rosso, DO: JCAD November 2025 Issue Highlights
Send us Fan MailDr. Del Rosso, Clinical Editor-in-Chief of the Journal of Clinical and Aesthetic Dermatology, discusses highlights from new research published in the November 2025 issue of JCAD.
Extended-cut Podcast—James Del Rosso, DO, and David G. Cotter, MD, PhD: Targeting the IL-31 Neuroimmune Pathway for Treating Prurigo Nodularis
Send us Fan MailDrs. Del Rosso and Cotter discuss advances in the molecular understanding of prurigo nodularis, which have enabled the development of targeted pharmaceuticals that treat the root of this condition.
James Del Rosso, DO: JCAD October 2025 Issue Highlights
Send us Fan MailDr. Del Rosso, Clinical Editor-in-Chief of the Journal of Clinical and Aesthetic Dermatology, discusses highlights from new research published in the October 2025 issue of JCAD.
David G. Cotter, MD, PhD: The Ideal Patient Candidate for Deuruxolitinib for Patients with Alopecia Areata
Send us Fan MailDr. Cotter discusses providing rapid hair regrowth in patients with alopecia areata.
David G. Cotter, MD, PhD: Utilizing the 31-gene Expression Profile Test in Patients with Melanoma
Send us Fan MailDr. Cotter discusses results of an expert consensus panel of the 31-gene expression profile test for patients with Melanoma.
David G. Cotter, MD, PhD: Providing Regrowth of Hair in Patients with Alopecia Areata
Send us Fan MailDr. Cotter discusses providing effective treatment for patients with alopecia areata
James Del Rosso, DO: JCAD September 2025 Issue Highlights
Send us Fan MailDr. Del Rosso, Clinical Editor-in-Chief of the Journal of Clinical and Aesthetic Dermatology, discusses highlights from new research published in the September 2025 issue of JCAD.
James Del Rosso, DO: JCAD August 2025 Issue Highlights
Send us Fan MailDr. Del Rosso, Clinical Editor-in-Chief of the Journal of Clinical and Aesthetic Dermatology, discusses highlights from new research published in the August 2025 issue of JCAD.
JCAD Dialogues and Reviews: Updates in Photoprotection and Recent Indication Expansions in Psoriasis and Rosacea
Send us Fan MailDr. Del Rosso discusses advancements in photoprotection formulations, as well as recent FDA approvals that have expanded treatment options for rosacea and psoriasis.
James Del Rosso, DO: JCAD June 2025 Issue Highlights
Send us Fan MailDr. Del Rosso, Clinical Editor-in-Chief of the Journal of Clinical and Aesthetic Dermatology, discusses highlights from new research published in the June 2025 issue of JCAD.
Extended-cut Podcast— Naiem Issa, MD, PhD, and Christopher Bunick, MD, PhD: Mechanisms of Dupilumab-associated Arthralgia in Patients with Atopic Dermatitis
Send us Fan MailIn this extended cut from JCAD’s recent Journal Review video series, Drs. Issa and Bunick dive into the possible mechanistic explanations behind arthralgia associated with dupilumab, which was detailed in a case series by Drs. Issa and Bunick and their colleagues in the May issue of The Journal of Clinical and Aesthetic Dermatology.
James Del Rosso, DO: JCAD May 2025 Issue Highlights
Send us Fan MailDr. Del Rosso, Clinical Editor-in-Chief of the Journal of Clinical and Aesthetic Dermatology, discusses highlights from new research published in the May 2025 issue of JCAD.
James Del Rosso, DO: JCAD April 2025 Issue Highlights
Send us Fan MailDr. Del Rosso, Clinical Editor-in-Chief of the Journal of Clinical and Aesthetic Dermatology, discusses highlights from new research published in the April 2025 issue of JCAD.
James Del Rosso, DO: JCAD February 2025 Issue Highlights
Send us Fan MailDr. Del Rosso, Clinical Editor-in-Chief of the Journal of Clinical and Aesthetic Dermatology, discusses highlights from new research published in the February 2025 issue of JCAD.
JCAD Dialogues and Reviews: Highlighting a Vitiligo Roundtable Discussion in JCAD
Send us Fan MailDr. James Del Rosso discusses a recent supplement that reviews insights about the challenges faced by both patients and clinicians in managing vitiligo.
JCAD Dialogues and Reviews: Considerations for Antibiotic Adverse Events
Send us Fan MailDr. Del Rosso discusses potential adverse events that can occur when treating patients with trimethoprim-sulfamethoxazole.
James Del Rosso, DO: JCAD January 2025 Issue Highlights
Send us Fan MailDr. Del Rosso, Clinical Editor-in-Chief of the Journal of Clinical and Aesthetic Dermatology, discusses highlights from new research published in the January 2025 issue of JCAD.
James Del Rosso, DO: Dermatology Year in Review 2024
Send us Fan MailDr. Del Rosso reviews some of the most impactful research developments and drug approvals seen by the dermatology world in 2024.
JCAD Dialogues and Reviews: Spotlight on a Newly Approved Treatment for Rosacea
Send us Fan MailDr. Del Rosso discusses warning signs of serious adverse events related to trimethoprim-sulfamethoxazole prescribed to patients with acne.
James Song, MD: Live from Elevate-Derm West—Why Older Immunosuppressant Agents are Still Relevant in 2024
Send us Fan MailDr. Song provides helpful clinical tips for treating patients with methotrexate.
James Song, MD: Live from Elevate-Derm West—New Topical and Systemic Agents for Atopic Dermatitis
Send us Fan MailDr. Song provides an extensive overview of what’s new and emerging in atopic dermatitis treatment.
James Del Rosso, DO: New and Exciting Indications for Bimekizumab, Nemolizumab, and Lebrikizumab
Send us Fan MailDr. Del Rosso discusses three exciting new indications for drugs in dermatology and how these approvals will impact clinical practice.
James Del Rosso, DO: JCAD October 2024 Issue Highlights
Send us Fan MailDr. Del Rosso, Clinical Editor-in-Chief of the Journal of Clinical and Aesthetic Dermatology, discusses highlights from new research published in the October 2024 issue of JCAD.
Leon Kircik, MD: Recent IL-17 Inhibitor Approval for Patients with Psoriasis
Send us Fan MailDr. Kircik discusses a recent FDA-approval of an IL-17 inhibitor that has demonstrated to be safe and effective in patients with psoriasis.
James Del Rosso, DO: Diagnostic Pearls for Psoriasis
Send us Fan MailDr. Del Rosso discusses how to provide the correct treatment for the various presentations of psoriasis along with the impact psoriatic arthritis can have on these patients.
Joel Gelfand, MD, MSCE, FAAD: Managing Cardiovascular Risk in Patients with Psoriasis
Send us Fan MailDr. Gelfand discusses how to treat patients with psoriasis in terms of cardiovascular risk. He encourages clinicians to educate their patients about these events and the potential side effects they present.
James Del Rosso, DO: Consulting Patients with Psoriasis on Biologic Therapy
Send us Fan MailDr. Del Rosso discusses ways in which he’s modified his consultation style when speaking to patients with psoriasis who are about to commence treatment with a biologic.
George Martin, MD: The Utilization of TNF Inhibitors for Psoriasis
Send us Fan MailGeorge Martin, MD, discusses the specific role TNF inhibitors play for the treatment of psoriasis along with an important safety implication to be aware of for treating patients during pregnancy.
James Del Rosso, DO: Identifying Appropriate Patients for TNF inhibitors
Send us Fan MailDr. Del Rosso discusses biologic options for treating patients with psoriasis and psoriatic arthritis as well as pregnant patients.
Linda Stein Gold, MD: Updates in Systemic Therapies for Psoriasis
Send us Fan MailDr. Stein Gold discusses insights from clinical trials on new and upcoming systemic agents for psoriasis, including deucravacitinib and bimekizumab.
George Martin, MD: The Current Role of TNF Inhibitors for Psoriasis
Send us Fan MailGeorge Martin, MD, discusses TNF inhibitors for the treatment of psoriasis and how these classic biologic agents currently fit into the ever-expanding arsenal of drugs for psoriasis.
Raj Chovatiya, MD, PhD: Mechanisms of Atopic Dermatitis Therapies
Send us Fan MailRaj Chovatiya, MD, PhD, Director of the Center for Eczema and Itch at the Department of Dermatology at Northwestern University Feinberg School of Medicine, reviews the mechanisms of action of currently available treatments for atopic dermatitis, including JAK inhibitors and biologic medications, and details how these medications work differently to reduce inflammation associated wi
Nicole Keeter, MSHS, PA-C: Incorporating Topical and Oral Treatments into Your Practice
Send us Fan MailNicole Keeter, MSHS, PA-C, describes how to implement various JAK inhibitors into practice for the treatment of atopic dermatitis, psoriasis, and alopecia areata. She discusses how utilizing these JAK inhibitors in the treatment of atopic dermatitis has shown to provide a rapid decrease in symptoms, particularly pruritus.
Nicole Keeter, MSHS, PA-C: Focusing on Safety Consideration for the Prescription of JAK Inhibitors
Send us Fan MailAfter reviewing notable safety considerations for systemic and topical Janus kinase inhibitors for patients with atopic dermatitis, Nicole Keeter, PA-C, describes steps she has taken to become more comfortable prescribing these agents to her patients with AD and discusses important tips for counseling these patients on adverse events and black box warnings.
James Del Rosso, DO: Topical Treatment for Atopic Dermatitis
Send us Fan MailDr. James Del Rosso reviews various common treatments for atopic dermatitis, specifically topical agents that have demonstrated effectiveness for patients.
Peter Lio, MD: The Evolution of Topical JAK Inhibitors
Send us Fan MailPeter Lio, MD, Assistant Professor of Clinical Dermatology and Pediatrics at Northwestern University’s Feinberg School of Medicine, discusses the development of JAK inhibitors over the years, and reviews the increase in reliability among both oral and topical treatments for atopic dermatitis.
James Del Rosso, DO: The Benefits of Topical JAK Inhibitors
Send us Fan MailDr. James Del Rosso discusses the benefits of topical JAK inhibitors over oral JAK inhibitors for the treatment of atopic dermatitis.
Lisa Swanson, MD: Things to Consider When Starting Patients on JAK Inhibitors
Send us Fan MailLisa Swanson, MD, a board-certified dermatologist and pediatric dermatologist with Ada West Dermatology in Boise, Idaho, reviews the role that Janus kinases (JAKs) play in the inflammatory process and the benefits of inhibiting this enzyme when treating patients with atopic dermatitis. She also elaborates upon her experiences using the newly approved JAK inhibitors in her own patie
Lisa Swanson, MD: Counseling Patients on JAK Inhibitors
Send us Fan MailLisa Swanson, MD, a board-certified dermatologist and pediatric dermatologist with Ada West Dermatology in Boise, Idaho, discusses how she intends to incorporate newly approved JAK inhibitors into her atopic dermatitis treatment algorithm and her strategies for patient counseling when treating with these agents.
Doris Day, MD: The Effect of Stress on Hair Health
Send us Fan MailDr. Day discusses the effect of stress on hair health.
Raj Chovatiya, MD, PhD: Discussing Atopic Dermatitis Treatment Risks with Patients
Send us Fan MailRaj Chovatiya, MD, PhD, Director of the Center for Eczema and Itch at the Department of Dermatology at Northwestern University Feinberg School of Medicine, discusses how he addresses questions from his patients with AD regarding potential adverse events and warnings associated with treatments for AD.
Douglas DiRuggiero, DMSc, PA-C: Safety of JAK Inhibitors for Atopic Dermatitis
Send us Fan MailDouglas DiRuggiero, DMSc, PA-C, discusses the exciting renaissance occurring in the realm of topical treatments for atopic dermatitis.
Matt Zirwas, MD: Patient Preparatory Guidance for Topical JAK Inhibitors
Send us Fan MailMatthew Zirwas, MD, provides guidance on speaking with patients with atopic dermatitis about treating their condition with topical JAK inhibitors.
Douglas DiRuggiero, DMSc, PA-C: An Overview of JAK Inhibitors for Atopic Dermatitis
Send us Fan MailDouglas DiRuggiero, DMSc, PA-C, discusses the mechanism of action and efficacy of topical and systemic JAK inhibitors for the treatment of atopic dermatitis.
Matt Zirwas, MD: An Overview of Janus-kinase (JAK) inhibitors for Atopic Dermatitis
Send us Fan MailMatthew Zirwas, MD, discusses the efficacy, benefits, and safety profile of topical and systemic JAK inhibitors for the treatment of atopic dermatitis.
Recommended
Effective Weight Loss for Moms | High protein, Strength Training, Lose Weight, Meal Planning, Fat Loss, Healthy Habits
The Human-Animal Connection - Pet Life Radio Original
Infinite Health with Dr. Arasi Maran
The Daily
World News Tonight with David Muir
English Vocabulary Help
The Joe Rogan Experience
TED Talks Daily
Learn English B1 with Daily News | English Listening Practice
Talk About Talk - Executive & Leadership Communication Skills
English with Olivia | Slow Conversations & Vocabulary
Stand In The Circle
